SPOTLIGHT: PerkinElmer paying $300M for ViaCell

PerkinElmer is buying ViaCell for $300 million, aiming to grow the latter's cord-blood banking business and spin off its drug-discovery unit, which is working on stem-cell-based remedies for cancer, heart disease, and diabetes. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.